Meeting
2020 ASCO Virtual Scientific Program
Pretherapeutic 68Ga-DOTATATE PET SUV predictors of survival of radionuclide therapy for metastatic neuroendocrine tumors.
Authors
Rahul Ladwa
Princess Alexandra Hospital & University of Queensland, Brisbane, Australia
Rahul Ladwa , David A. Pattison , Jye Smith , Steven Goodman , Matthew E. Burge , Stephen Rose , Nicholas Dowson , David Wyld
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Neuroendocrine/Carcinoid
Citation
J Clin Oncol 38: 2020 (suppl; abstr 4609)
DOI
10.1200/JCO.2020.38.15_suppl.4609
Abstract #
4609
Poster Bd #
217
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Tumor PD-L1 expression and gene panel mutational profile as outcome predictors of PD-1-based checkpoint inhibition therapy in metastatic melanoma: A prospective multicenter DeCOG study.
First Author: Selma Ugurel
Poster
2018 ASCO Annual Meeting
Two novel registry-based prediction models for overall survival in patients with metastatic esophageal or gastric cancer.
First Author: Héctor van den Boorn
Poster
2015 ASCO Annual Meeting
Clinical predictors of 5-year survival in patients with EGFR-mutant metastatic NSCLC treated with EGFR-TKIs.
First Author: Jessica Jiyeong Lin
Poster
2024 ASCO Genitourinary Cancers Symposium
Outcomes for patients with mCRPC and liver metastasis receiving 177-Lu-PSMA-617 treatment.
First Author: Miguel Muniz